Breaking News Instant updates and real-time market news.

EPZM

Epizyme

$18.22 /

+2.9 (+18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09

Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat

Epizyme reported "positive, mature data" at the 2019 American Society of Hematology Annual Meeting from its ongoing Phase 2 trial of tazemetostat, an oral EZH2 inhibitor, as a monotherapy for patients with follicular lymphoma, both with or without EZH2 activating mutations, who have received at least two prior lines of systemic therapy. The data show that treatment with tazemetostat demonstrated "meaningful" clinical activity as assessed by both investigators and an Independent Review Committee, and was generally well tolerated in both FL patients with EZH2 activating mutations and FL patients with wild-type EZH2, the company said. The IRC assessment was conducted for inclusion in Epizyme's planned NDA submission to the Food and Drug Administration in December 2019. As assessed by the IRC, as of an August 9, 2019 data cutoff date, tazemetostat treatment resulted in: Objective response rate of 69% for patients with an EZH2 mutation and 35% for patients with wild-type EZH2; Median duration of response of 11 months for patients with an EZH2 mutation and 13 months for patients with wild-type EZH2; Median progression-free survival of 14 months for patients with an EZH2 mutation and 11 months for patients with wild-type EZH2; Overall survival has not yet been reached for either FL patient. "Follicular lymphoma remains an incurable disease today, and it's essential that patients be able to receive treatment for an extended period of time," said Dr. Shefali Agarwal, Chief Medical Officer of Epizyme. "We believe the clinically meaningful benefit of tazemetostat seen across both FL patient populations in this trial, along with its continued tolerability, are impressive findings. We are particularly pleased with the robust response rates, extended durability and consistency of data as assessed by investigators and independent reviewers. These data support tazemetostat's potential to make a difference for FL patients, and we look forward to submitting our NDA for both patient populations later this month."

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

EPZM Epizyme
$18.22 /

+2.9 (+18.93%)

12/06/19
Fly Intel: Top five analyst upgrades
12/05/19 Morgan Stanley
Morgan Stanley upgrades Epizyme to Overweight ahead of lymphoma data
12/05/19 Morgan Stanley
Epizyme upgraded to Overweight from Equal Weight at Morgan Stanley
06/13/19 H.C. Wainwright
Epizyme selloff yesterday an overreaction, says H.C. Wainwright

TODAY'S FREE FLY STORIES

Earnings
California Water Service reports Q4 EPS 24c, consensus 30c » 09:22
02/27/20
02/27
09:22
02/27/20
09:22
CWT

California Water Service

$52.77 /

-0.18 (-0.34%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Syndicate
Oramed 5.25M share Spot Secondary priced at $4.00 » 09:22
02/27/20
02/27
09:22
02/27/20
09:22
ORMP

Oramed

$4.65 /

-0.21 (-4.32%)

National Securities acted…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Microsoft's underlying demand intact despite warning, says Morgan Stanley » 09:21
02/27/20
02/27
09:21
02/27/20
09:21
MSFT

Microsoft

$170.20 /

+2.14 (+1.27%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Capital One adds Eileen Serra to board » 09:20
02/27/20
02/27
09:20
02/27/20
09:20
COF

Capital One

$92.83 /

+0.06 (+0.06%)

Capital One has appointed…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
GeoVax Labs to present at World Immunotherapy Congress 2020 » 09:19
02/27/20
02/27
09:19
02/27/20
09:19
GOVX

GeoVax Labs

$0.00 /

+ (+0.00%)

GeoVax Labs announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Options
Overnight activity included 1837 trades in SPX and 138 trades in VIX » 09:18
02/27/20
02/27
09:18
02/27/20
09:18
SPX

S&P 500

$0.00 /

+ (+0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00 /

+ (+0.00%)

1837 trades were executed…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
NetEase downgraded to Neutral from Outperform at Macquarie » 09:17
02/27/20
02/27
09:17
02/27/20
09:17
NTES

NetEase

$345.55 /

+7.47 (+2.21%)

Macquarie downgraded…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
L Brands price target raised to $24 from $18 at MKM Partners » 09:17
02/27/20
02/27
09:17
02/27/20
09:17
LB

L Brands

$22.77 /

-0.76 (-3.23%)

MKM Partners analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Riverview Bancorp enters trading plan with Keefe, Bruyette & Woods » 09:16
02/27/20
02/27
09:16
02/27/20
09:16
RVSB

Riverview Bancorp

$6.97 /

-0.05 (-0.71%)

The Board of Directors of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Downgrade
Aurora Cannabis downgraded to Sell from Neutral at Bryan Garnier » 09:15
02/27/20
02/27
09:15
02/27/20
09:15
ACB

Aurora Cannabis

$1.51 /

+ (+0.00%)

Bryan Garnier analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Riverview Bancorp announces stock repurchase program up to 500k shares » 09:15
02/27/20
02/27
09:15
02/27/20
09:15
RVSB

Riverview Bancorp

$6.97 /

-0.05 (-0.71%)

Riverview Bancorp…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
Fed policy outlook: the markets may force the FOMC to ease policy » 09:15
02/27/20
02/27
09:15
02/27/20
09:15

Fed policy outlook: the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Hot Stocks
Equity Residential CIO Alan George to retire, Alexander Brackenridge to succeed » 09:14
02/27/20
02/27
09:14
02/27/20
09:14
EQR

Equity Residential

$83.38 /

-0.165 (-0.20%)

Equity Residential…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Advaxis announces clinical data of ongoing Phase 1/2 ADXS-503 trial » 09:13
02/27/20
02/27
09:13
02/27/20
09:13
ADXS

Advaxis

$0.89 /

+0.0145 (+1.66%)

Advaxis announced updated…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Recommendations
TJX price target raised to $74 from $70 at MKM Partners » 09:13
02/27/20
02/27
09:13
02/27/20
09:13
TJX

TJX

$64.05 /

+4.28 (+7.16%)

MKM Partners analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Fly Intel: Pre-market Movers » 09:13
02/27/20
02/27
09:13
02/27/20
09:13
GILD

Gilead

$74.70 /

+4.57 (+6.52%)

, SQ

Square

$76.63 /

-0.38 (-0.49%)

, SPCE

Virgin Galactic

$28.69 /

-4.96 (-14.74%)

, TSLA

Tesla

$778.39 /

-21.365 (-2.67%)

, SRNE

Sorrento Therapeutics

$2.24 /

-0.01 (-0.44%)

, ETSY

Etsy

$50.64 /

+0.73 (+1.46%)

, BUD

AB InBev

$66.35 /

-0.5 (-0.75%)

, DISCA

Discovery

$26.50 /

-0.925 (-3.37%)

, QEP

QEP Resources

$2.16 /

-0.105 (-4.64%)

, PLAN

Anaplan

$57.97 /

+0.87 (+1.52%)

, PTLA

Portola Pharmaceuticals

$12.51 /

-0.13 (-1.03%)

HIGHER: Gilead (GILD), up…

HIGHER: Gilead (GILD), up 7% after announcing the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19, or novel coronavirus... Sorrento Therapeutics (SRNE), up 1% after announcing it has initiated a clinical and manufacturing collaboration with Celularity to expand the therapeutic use of Celularity's CYNK-001, an allogeneic, off-the-shelf, placental-derived Natural Killer cell therapy, to the treatment and prevention of coronavirus infections. UP AFTER EARNINGS: Square (SQ), up 6%... Etsy (ETSY), up 9%. DOWN AFTER EARNINGS: AB InBev (BUD), down 9%... Discovery (DISCA), down 6%... QEP Resources (QEP), down 19%... Anaplan (PLAN), down 32%... Portola Pharmaceuticals (PTLA), down 15%. ALSO LOWER: Tesla (TSLA), down 6% after Bloomberg reported registrations of new Teslas in China plunged 46% last month as the coronavirus outbreak adds to a slump in the country's car market... Virgin Galactic (SPCE), down 16% after Morgan Stanley analyst Adam Jonas downgraded shares to Equal Weight from Overweight and Credit Suisse analyst Robert Spingarn also downgraded the stock to Neutral from Outperform.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Nutrien price target lowered to $54 from $61 at Susquehanna » 09:13
02/27/20
02/27
09:13
02/27/20
09:13
NTR

Nutrien

$40.48 /

-0.12 (-0.30%)

Susquehanna analyst Don…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Syndicate
Lianluo Smart Limited raises $3.4M in a registered direct offering » 09:12
02/27/20
02/27
09:12
02/27/20
09:12
LLIT

Lianluo Smart Limited

$0.89 /

+0.185 (+26.24%)

Lianluo Smart Limited has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Hot Stocks
Gevo secures funding from Queensland W2B fund » 09:12
02/27/20
02/27
09:12
02/27/20
09:12
GEVO

Gevo

$1.61 /

-0.06 (-3.59%)

Gevo has been awarded…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Acme United reports Q4 EPS 28c, one est. 17c » 09:10
02/27/20
02/27
09:10
02/27/20
09:10
ACU

Acme United

$23.50 /

-0.69 (-2.85%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
Hot Stocks
Sigma Labs announces one-for-ten reverse stock split » 09:10
02/27/20
02/27
09:10
02/27/20
09:10
SGLB

Sigma Labs

$0.59 /

-0.015 (-2.48%)

Sigma Labs will effect a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General news
The 8k initial claims rise to 219k » 09:10
02/27/20
02/27
09:10
02/27/20
09:10

The 8k initial claims…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Hot Stocks
Blackstone announces strategic investment in Dealpath » 09:09
02/27/20
02/27
09:09
02/27/20
09:09
BX

Blackstone

$56.03 /

-0.435 (-0.77%)

Dealpath announced a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Papa John's price target raised to $67 from $60 at MKM Partners » 09:09
02/27/20
02/27
09:09
02/27/20
09:09
PZZA

Papa John's

$61.51 /

-6 (-8.89%)

MKM Partners analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Northcoast cuts Aaron's to Neutral on core and Progressive growth uncertainty » 09:09
02/27/20
02/27
09:09
02/27/20
09:09
AAN

Aaron's

$41.45 /

-1.35 (-3.15%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.